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Clinical and epidemiological studies suggest that premature ageing and increased morbidity and mortality is
present in Ullrich-Turner syndrome. We studied telomere restriction fragment length (TRFL) in 30 women
with Ullrich-Turner syndrome and 30 age-matched control women. All Turner women had the 45,X karyotype
verified by karyotyping. We found no difference in the mean TRFL in the young age group (TS: 7011+521 vs
C: 7285+917 bp, P = 0.3), or in the older age group (TS: 7357+573 vs C: 7221+621 bp, P = 0.6). In
conclusion, our data suggest that Ullrich-Turner syndrome is not associated with excessive telomere loss, at
least when studied in peripheral blood leucocytes, and thus quite different from other premature ageing
syndromes. European Journal of Human Genetics (2001) 9, 877 – 879.
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The essential features of Ullrich-Turner syndrome are growth
retardation with reduced final height, gonadal insufficiency
(female sex hormone deficiency) and infertility. Patients with
Ullrich-Turner syndrome exhibit increased morbidity
throughout their entire lifespan.1 Thus, several studies have
documented that patients with Ullrich-Turner syndrome
have increased frequency of cardiovascular diseases,1,2
compromised immune response and a high prevalence of
thyroid diseases and thyroid antibodies,3 early sensineuronal
hearing loss,4 abnormal endocrine functions, impaired
glucose tolerance (being present in 50% of adult patients),
and type 2 diabetes2,5 (diabetes is viewed by some as a
segmental progeroid syndrome6), a low bone mineral
content7 – 9 and a high frequency of osteoporosis and
fractures.1,10 Finally, the life expectancy is decreased in
females with Ullrich-Turner syndrome.11 – 13 The available
data suggest that Ullrich-Turner syndrome is associated with
premature ageing and increased early morbidity and
mortality.
Telomeres are nucleoprotein complexes at the ends of
chromosomes consisting of tandem arrays of TTAGGG
nucleotide repeats of up to 10 – 15 kilobase-pairs (kb). They
are essential for chromosome stability and for preventing
degradation and abnormal chromosomal recombinations.14
During cell division, there is a continuous process of telomere
shortening because of the nature of the DNA replication
process.15 It has been suggested that shortened telomeres
signal a growth check-point that triggers irreversible cell
cycle-arrest manifested as cellular senescence.15,16 Excessive
telomere shortening has been observed in fibroblasts from
patients with premature ageing syndromes such as Werner’s
syndrome and Hutchinson-Gilford progeria17,18 and in
peripheral blood leukocytes (PBL) in patients with ataxia
telangiectasia19 and Down’s syndrome.20 Furthermore, estro-
gen activates telomerase, a cellular reverse transcriptase that
catalyses synthesis and extension of telomeric DNA, activity
both directly and indirectly by upregulation of hTERT
(human telomerase reverse transcription subunit),21 thus
indicating a causative role of estrogen in regulating telomer-
ase in tissues expressing the enzyme. Recently, it has also
been shown that accelerated telomere shortening is seen in
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the inactive X chromosome in female humans,22 the
significance of which is not clear at the moment.
In the present study we tested the hypothesis that Ullrich-
Turner syndrome is associated with excessive telomere
shortening. We determined telomere fragment length
employing DNA obtained from a large sample of patients
with Ullrich-Turner syndrome (45,X) and age-matched
controls.
Thirty women with Ullrich-Turner syndrome and 30 age
matched control women were studied (Table 1). All women
with Ullrich-Turner syndrome were not menstruating and
most were taking female hormone replacement therapy. All
had the 45,X karyotype verified by karyotyping. DNA was
extracted from PBL using a standard method.23 Mean
telomere restriction fragment length (TRFL) was measured
by Southern blotting analysis as previously described.24 As
TRFL decreases with age, the participants were divided into
two groups. A young group with participants between 20 – 30
years, and an older group with participants between 40 – 50
years (Table 1). Data were examined by Students two-tailed
unpaired t-test. Pearson correlation was used to examine the
relation between TRFL and duration of oestrogen therapy in
women with Ullrich-Turner syndrome. Results are expressed
as the mean+standard deviation (SD). Significance levels
under 5% were considered significant. All statistical calcula-
tions were done with SPSS for Windows version 10.0 (SPSS
Inc., Chicago, Illinois, USA) on a Pentium PC.
We found no difference in the mean TRFL in the young age
group (TS: 7011+521 vs C: 7285+917 bp, P = 0.3) (Figure 1).
Similarly no difference in TRFL was seen in the older age
group (TS: 7357+573 vs C: 7221+621 bp, P = 0.6). There was
no age-related changes in the mean TRFL between young and
old age groups in patients with Ullrich-Turner syndrome or in
controls. We found no correlation between duration of
oestrogen treatment in the group of women with Ullrich-
Turner syndrome and the mean TRFL (r = 0.107, P = 0.6).
This was also true after correction for chronological age
(r = 0.095, P = 0.6).
Our data suggest that Ullrich-Turner syndrome is not
associated with excessive telomere loss and thus quite
different from other premature ageing syndromes. Our
inability to detect differences in the mean TRFL between
patients with TS and controls was not due to the sample size
as our study has a 90% power to detect a 10% difference in
the mean TRFL between patients with TS and age-matched
controls.
While epidemiological and clinical studies suggest that
Ullrich-Turner syndrome is associated with excessive mor-
bidity and mortality, the mean TRFL was not a sensitive
marker for this phenotype. However, our study has some
limitations. First, we studied an unselected group of patients
with Ullrich-Turner syndrome which may be heterogenous
with respect to their risk factors and disease complication. A
group of patients with Ullrich-Turner syndrome with
evidence of morbidity may reveal abnormalities in the mean
TRFL. Second, we measured the mean TRFL. As different
chromosomes may have different rates of telomere short-
ening, a study of telomere length of individual chromosomes
may be more informative.22 Third, we measured mean TRFL
in PBL which may have a high turnover and renewal from
hematopoietic stem cells in the bone marrow. Studies of
other cell types from the organs affected by excessive
morbidity eg, endothelial cells or osteoblasts, may reveal
abnormalities that were not detected in the PBL. However,
recent data suggest that although the absolute telomere
restriction fragment length may be different in different
tissues from the same individual, there is a rather tight
correlation between the TRFL in different healthy tissues and
this suggests that the genetic determination of the regulation
of TRFL is tissue-independent.25
Alternatively, our findings may suggest that other factors
apart from intrinsic cellular defects are responsible for the
observed increased morbidity and mortality in patients with
TS. Endocrine deficiency (eg, estrogen deficiency) which is
almost always present in Ullrich-Turner syndrome or other
hormonal deficiencies, like androgen26,27 or growth hor-
mone insufficiencies28 may lead to metabolic abnormalities
and increased morbidity. Also, other yet unknown factors or
genes located on the ‘missing’ X chromosomes might
contribute to the Ullrich-Turner syndrome phenotype.
Studying the relative contributions of these factors remains
to be determined.
Table 1 Age, number and mean telomere restriction
fragment length (TRFL) in young and old individuals
Age/years Number TRFL/bp
Young Ullrich-Turner syndrome 24.8+3.0 15 7011+521
Controls 23.7+1.9 15 7285+917
Old Ullrich-Turner syndrome 42.9+6.5 15 7357+573
Controls 47.1+3.8 15 7221+621
Figure 1 Representative Southern blot analysis of individual
mean telomere restriction fragment length for Turner (T) vs
control (C) samples.
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